Precision Medicine for L/GCMN and Melanoma 2
About this study
The primary objective is to evaluate the possibility of using minimally and non-invasive technologies (skin patch and breath analyzer) based on the detection of volatile organic compounds (VOCs) for the early identification of metastases. The secondary objective is to evaluate the usability of these technologies in the follow up of high-risk melanoma patients.
- Condition
- Melanoma (Skin Cancer), Nevi and Melanomas, Congenital Melanocytic Nevus
- Tested
- Breath analyzer, Skin patch, Liquid biopsy
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 4
- Minimum age: 18 years
- Study condition: Melanoma (Skin Cancer), Nevi and Melanomas, Congenital Melanocytic Nevus
- Be over 18 years old
- Have a histopathological confirmed melanoma diagnosis (stage II, III or IV AJCC)
Exclusion 2
- Not signing the informed consent form
- Present other cancers or chronic diseases (such as diabetes, asthma, etc.), which may affect the volatile organic compound profiles
Where
3 sites, 3 recruiting
Hospital Clínic Barcelona
Barcelona, Spain
Hospital Clínic Barcelona
Barcelona, Spain
Hospital Clínic de Barcelona (Dermatology service)
Barcelona, Spain
Contact
-
Susana Puig Sardà, PhD, MD
+34932275400 spuig@clinic.cat
-
Adrián López Canosa, PhD
Potential match only. Final eligibility is determined by the study team.